Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04902820 · ClinicalTrials.gov registry record · NA

PrEPTECH Phase 2 Study of a PrEP Telehealth Intervention

A NA study of HIV and Telemedicine, sponsored by ETR Associates.

Completed
Registry status
NA
Development phase
229
Enrollment target
1
Study location

NCT04902820: Completed NA study of HIV and Telemedicine, sponsored by ETR Associates.

NCT04902820 is a NA study of HIV and Telemedicine that has completed, run by ETR Associates. The registered enrollment target is 229 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04902820, a NA study of HIV and Telemedicine, has completed, sponsored by ETR Associates.

COMPLETED
Registry status
NA
Development phase
229 participants
Enrollment target
1
Study location

Study Summary

PrEPTECH Phase 2 is a 2-arm randomized controlled trial to assess the effectiveness of a telehealth intervention in increasing PrEP uptake among cisgender men and transgender women who have sex with men over six months. Participants (N = 400) will be randomized equally into one of two study conditions, treatment with a telehealth intervention called PrEPTECH or a control condition consisting of treatment as usual plus access to a listing of online and local PrEP resources, and assessed via surveys at baseline and at 90 and 180 days after baseline. Randomization of participants will be stratified by participant sub-group (adult men who have sex with men, adolescent men who have sex with men, and transgender women). The baseline and follow-up assessments will include questions on demographic characteristics, measures related to our primary and secondary outcomes, and psychosocial measures. The primary outcomes measure is self-reported PrEP initiation at 3-month post enrollment, the percentage of participants reporting having taken at least one dose of PrEP medication by that time point. In addition, usage data and medical data will be collected and analyzed.

Primary Outcome

Percentage of participants reporting having taken at least one dose of PrEP medication at any point during the intervention period

Interventions

  • OTHER PrEPTECH website
  • OTHER Online PrEP resource list

Study Locations (1)

California

  • ETR - Scotts Valley

Trial Details

FieldValue
Enrollment Target 229 participants
Start Date 2022-02-12
Est. Completion 2023-06-30
Phase NA
ETR Associates

6 total trials

What the finished NCT04902820 record still lists

NCT04902820 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (48% lower).

The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which PrEPTECH website is the first listed.

NCT04902820 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04902820 about?

NCT04902820 is a clinical study titled "PrEPTECH Phase 2 Study of a PrEP Telehealth Intervention". PrEPTECH Phase 2 is a 2-arm randomized controlled trial to assess the effectiveness of a telehealth intervention in increasing PrEP uptake among cisgender men and transgender women who have sex with men over six months. Participants (N = 400) will be randomized equally into one of two study conditio...

What is the current status of trial NCT04902820?

This trial is currently completed. It is a NA study. The enrollment target is 229 participants. The study started on 2022-02-12. Estimated completion is 2023-06-30.

What conditions does trial NCT04902820 study?

This clinical trial studies the following conditions: HIV, Telemedicine, Pre-exposure Prophylaxis.

What interventions are being tested in trial NCT04902820?

The interventions under investigation include: PrEPTECH website (OTHER), Online PrEP resource list (OTHER).

Who is sponsoring clinical trial NCT04902820?

This trial is sponsored by ETR Associates, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04902820 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04902820's enrollment target sits among peer trials

229 94th of 303 higher than 210 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04902820, the US trial registry maintained by the National Library of Medicine. NCT04902820 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.